Harvard Bioscience, Inc. provided revenue guidance for the year 2022. The company expects year-over-year revenue growth in the range of 8% to 13% versus last year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.16 USD | -0.63% | -6.23% | -40.93% |
07/05 | Transcript : Harvard Bioscience, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
07/05 | Earnings Flash (HBIO) HARVARD BIOSCIENCE Posts Q1 Revenue $24.5M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.93% | 14Cr | |
+10.03% | 22TCr | |
+13.59% | 19TCr | |
+20.01% | 14TCr | |
+30.83% | 11TCr | |
+2.05% | 6.5TCr | |
+15.38% | 5.3TCr | |
+3.96% | 5.04TCr | |
+8.37% | 4.42TCr | |
+3.27% | 3.64TCr |
- Stock Market
- Equities
- HBIO Stock
- News Harvard Bioscience, Inc.
- Harvard Bioscience, Inc. Provides Revenue Guidance for the Year 2022